Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03781479
Recruitment Status : Recruiting
First Posted : December 20, 2018
Last Update Posted : January 25, 2019
Sponsor:
Information provided by (Responsible Party):
Catalyst Pharmaceuticals, Inc.

Brief Summary:
A two-period, two-treatment, crossover study to evaluate the safety, tolerability and efficacy of amifampridine phosphate in ambulatory patients diagnosed with spinal muscular atrophy (SMA) Type 3.

Condition or disease Intervention/treatment Phase
Muscular Atrophy, Spinal Drug: Amifampridine Phosphate Drug: Placebo Oral Tablet Phase 2

Detailed Description:
This randomized (1:1), double-blind, placebo-controlled, 2-period, 2-treatment, crossover, outpatient study is designed to evaluate the safety, tolerability and efficacy of amifampridine phosphate in ambulatory patients diagnosed with SMA Type 3. The study is planned to include approximately 12 male and female SMA Type 3 patients. The planned duration of participation for each patient is approximately 2 months, based upon length of dose titration and excluding the screening period, which can last up to 14 days. Patients should only be taking the assigned investigational product (amifampridine phosphate 10 mg tablets or matching placebo tablets), no new therapies are permitted during the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Amifampridine Phosphate in Ambulatory Patients With Spinal Muscular Atrophy (SMA) Type 3
Actual Study Start Date : January 21, 2019
Estimated Primary Completion Date : December 15, 2019
Estimated Study Completion Date : March 15, 2020


Arm Intervention/treatment
Experimental: amifampridine phophate - placebo
Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
Drug: Amifampridine Phosphate
Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
Other Name: 3,4 diaminopyridine phosphate

Drug: Placebo Oral Tablet
Placebo Oral Tablet

Experimental: placebo - amifampridine phophate
Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
Drug: Amifampridine Phosphate
Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
Other Name: 3,4 diaminopyridine phosphate

Drug: Placebo Oral Tablet
Placebo Oral Tablet




Primary Outcome Measures :
  1. Change from baseline in the Hammersmith Functional Motor Scale Expanded (HFMSE) [ Time Frame: Change from baseline in HFMSE score at the end of week 6 (end of Period 1) and change from baseline in HFMSE scare at the end of week 8 (end of Period 2) ]
    standardized measurement of muscle function



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Willing and able to provide written informed consent after the nature of the study has been explained and before the start of any research-related procedures.
  2. Male or female between the ages of 6 and 50 years.
  3. Genetically confirmed diagnosis of SMA Type 3.
  4. Able to walk independently for at least 30 meters.
  5. Not taking Nusinersen for the treatment of SMA (Nusinersen should be stopped at least 6 months before screening). Salbutamol is permitted only if the dose has been stable during the 6 months before screening.
  6. Able to swallow oral medication.
  7. Female patients of childbearing potential must have a negative pregnancy test (serum human chorionic gonadotropin [HCG] at Screening); and must practice an effective, reliable contraceptive regimen during the study and for up to 30 days following discontinuation of treatment.
  8. Ability to participate in the study based on overall health of the patient and disease prognosis, as applicable, in the opinion of the Investigator; and able to comply with all requirements of the protocol, including completion of study questionnaires.

Exclusion Criteria:

  1. Epilepsy and currently on medication for epilepsy.
  2. Concomitant use of medicinal products with a known potential to cause QTc prolongation.
  3. Patients with long QT syndromes.
  4. An electrocardiogram (ECG) within 6 months before starting treatment that shows clinically significant abnormalities, in the opinion of the Investigator.
  5. Breastfeeding or pregnant at Screening or planning to become pregnant at any time during the study.
  6. Treatment with an investigational drug (other than amifampridine), device, or biological agent within 6 months prior to Screening or while participating in this study.
  7. Surgery for scoliosis or joint contractures within the previous 6 months.
  8. Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confound the assessment of the patient.
  9. History of drug allergy to any pyridine-containing substances or any amifampridine excipient(s).
  10. Less than a 3-point improvement in HFSME from start of the Open label Run -in period to end of Run-in (Day 0).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03781479


Contacts
Layout table for location contacts
Contact: Lorenzo Maggi, MD +39-02-23942372 lorenzo.maggi@istituto-besta.it
Contact: Stanley Iyadurai, MD, PhD 305-420-3200 ext 139 siyadurai@catalystpharma.com

Locations
Layout table for location information
Italy
Neurological Institute Carlo Besta Recruiting
Milano, Lombardy, Italy, 20133
Contact: Lorenzo Maggi, MD       lorenzo.maggi@istituto-besta.it   
Sponsors and Collaborators
Catalyst Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Lorenzo Maggi, MD Carlo Besta Institute, Milan, Italy

Layout table for additonal information
Responsible Party: Catalyst Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03781479     History of Changes
Other Study ID Numbers: SMA-001
First Posted: December 20, 2018    Key Record Dates
Last Update Posted: January 25, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Catalyst Pharmaceuticals, Inc.:
Type 3

Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Atrophy
Muscular Atrophy, Spinal
Atrophy
Pathological Conditions, Anatomical
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Spinal Cord Diseases
Central Nervous System Diseases
Motor Neuron Disease
Neurodegenerative Diseases
Neuromuscular Diseases
Amifampridine
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Potassium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action